Immune to Cancer: The CRI Blog
-
CRI Funded Scientist
Rik G.H. Lindeboom, PhD
Cancer treatments often rely on the body’s own immune cells, particularly T cells, to recognize and attack… -
CRI Funded Scientist
Rachel S. Helms, PhD
Effective immunotherapies leverage the immune system to eliminate cancer and, therefore, rely on the proper development and… -
CRI Funded Scientist
Nastaran Fazel Modares, PhD
Liver cancer, also known as hepatocellular carcinoma (HCC), is a common cause of human death globally. Treatment… -
CRI Funded Scientist
Nadia Guerra, PhD
While there have been significant advancements in cancer treatment through immunotherapies, there is still an urgent need… -
CRI Funded Scientist
Matija Snuderl, MD
Chordomas are rare tumors arising from the clivus or sacrum. Chordomas are characterized by low mutational burden… -
CRI Funded Scientist
Masakazu Kamata, PhD
Brainstem glioma (BSG) is a highly aggressive brain tumor that arises from glial cells and has an… -
CRI Funded Scientist
Marco Ruella, MD
When Hodgkin Lymphoma (HL) comes back after treatment, it is very difficult to treat. CAR T immunotherapy… -
CRI Funded Scientist
Luisa F. Escobar-Hoyos, PhD
Dr. Escobar-Hoyos presents a groundbreaking approach to cancer treatment using an innovative RNA delivery system featuring the… -
CRI Funded Scientist
Karin Pelka, PhD
The discovery of new immunotherapy targets for solid tumors is limited by our poor understanding of howvimmune,…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.